Lixte Common Stock Shares Outstanding vs Cash Analysis

LIXT Stock

USD 2.67 0.10 3.61%

Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Common Stock Shares Outstanding and its Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

Common Stock Shares Outstanding vs Cash

Common Stock Shares Outstanding vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Common Stock Shares Outstanding account and Cash. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Lixte Biotechnology's Common Stock Shares Outstanding and Cash is -0.31. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Cash in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Common Stock Shares Outstanding and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Lixte Biotechnology Holdings are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Common Stock Shares Outstanding i.e., Lixte Biotechnology's Common Stock Shares Outstanding and Cash go up and down completely randomly.

Correlation Coefficient

-0.31

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Cash

Cash refers to the most liquid asset of Lixte Biotechnology, which is listed under current asset account on Lixte Biotechnology Holdings balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Lixte Biotechnology customers. The amounts must be unrestricted with restricted cash listed in a different Lixte Biotechnology account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

Issuance Of Capital Stock is likely to gain to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop 3,983 in 2024.

Lixte Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Current Assets	Common Stock Total Equity	Short Long Term Debt Total	Short Term Debt	Net Receivables	Inventory	Current Deferred Revenue	Net Tangible Assets	Preferred Stock Total Equity	Net Invested Capital
Total Assets		0.65	0.24	0.96	-0.97	-0.76	0.95	0.96	-0.28	0.76	0.24	1.0	-0.3	-0.32	0.46	0.81	-0.56	0.73	-0.11	-0.83	-0.66	0.4	0.35	0.58	0.72	0.95
Other Current Liab	0.65		0.46	0.63	-0.63	-0.72	0.63	0.64	0.03	0.7	0.46	0.65	-0.19	-0.3	0.41	0.68	-0.35	0.54	-0.23	-0.7	-0.47	0.42	0.72	0.37	0.55	0.66
Total Current Liabilities	0.24	0.46		0.21	-0.22	-0.45	0.22	0.23	0.18	0.43	1.0	0.24	0.13	-0.79	0.66	0.33	-0.13	0.26	-0.12	-0.22	-0.01	0.71	0.48	0.04	0.2	0.16
Total Stockholder Equity	0.96	0.63	0.21		-1.0	-0.84	1.0	1.0	-0.31	0.86	0.21	0.96	-0.4	-0.3	0.42	0.8	-0.56	0.83	-0.35	-0.88	-0.71	0.32	0.34	0.64	0.73	0.98
Net Debt	-0.97	-0.63	-0.22	-1.0		0.83	-1.0	-1.0	0.31	-0.85	-0.22	-0.97	0.38	0.3	-0.43	-0.79	0.6	-0.81	0.32	0.86	0.72	-0.33	-0.34	-0.63	-0.75	-0.97
Retained Earnings	-0.76	-0.72	-0.45	-0.84	0.83		-0.84	-0.84	0.35	-0.99	-0.45	-0.75	0.38	0.48	-0.51	-0.73	0.3	-0.86	0.59	0.91	0.71	-0.55	-0.69	-0.41	-0.79	-0.81
Cash	0.95	0.63	0.22	1.0	-1.0	-0.84		1.0	-0.31	0.86	0.22	0.95	-0.39	-0.3	0.43	0.78	-0.6	0.82	-0.36	-0.86	-0.72	0.32	0.33	0.63	0.75	0.97
Cash And Short Term Investments	0.96	0.64	0.23	1.0	-1.0	-0.84	1.0		-0.28	0.86	0.23	0.96	-0.4	-0.31	0.44	0.79	-0.59	0.83	-0.36	-0.86	-0.71	0.33	0.33	0.65	0.74	0.98
Common Stock Shares Outstanding	-0.28	0.03	0.18	-0.31	0.31	0.35	-0.31	-0.28		-0.33	0.18	-0.28	-0.01	0.01	0.04	-0.18	-0.17	-0.2	0.1	0.41	0.37	-0.03	-0.31	0.04	-0.35	-0.25
Other Stockholder Equity	0.76	0.7	0.43	0.86	-0.85	-0.99	0.86	0.86	-0.33		0.43	0.76	-0.44	-0.46	0.46	0.74	-0.34	0.89	-0.64	-0.89	-0.68	0.51	0.65	0.49	0.75	0.83
Total Liab	0.24	0.46	1.0	0.21	-0.22	-0.45	0.22	0.23	0.18	0.43		0.24	0.13	-0.79	0.66	0.33	-0.13	0.26	-0.12	-0.22	-0.01	0.71	0.48	0.04	0.2	0.16
Total Current Assets	1.0	0.65	0.24	0.96	-0.97	-0.75	0.95	0.96	-0.28	0.76	0.24		-0.29	-0.32	0.46	0.81	-0.56	0.73	-0.1	-0.83	-0.66	0.39	0.34	0.58	0.72	0.95
Common Stock	-0.3	-0.19	0.13	-0.4	0.38	0.38	-0.39	-0.4	-0.01	-0.44	0.13	-0.29		-0.35	0.16	-0.61	0.42	-0.77	0.51	0.3	0.18	0.19	-0.21	-0.66	-0.11	-0.45
Property Plant And Equipment Net	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	0.01	-0.46	-0.79	-0.32	-0.35		-0.55	-0.17	-0.08	-0.2	0.12	0.32	0.11	-0.87	-0.29	0.03	-0.33	-0.24
Accounts Payable	0.46	0.41	0.66	0.42	-0.43	-0.51	0.43	0.44	0.04	0.46	0.66	0.46	0.16	-0.55		0.4	-0.18	0.31	0.0	-0.51	-0.54	0.44	0.29	-0.13	0.61	0.41
Non Current Assets Total	0.81	0.68	0.33	0.8	-0.79	-0.73	0.78	0.79	-0.18	0.74	0.33	0.81	-0.61	-0.17	0.4		-0.49	0.85	-0.16	-0.73	-0.5	0.24	0.51	0.58	0.53	0.83
Other Current Assets	-0.56	-0.35	-0.13	-0.56	0.6	0.3	-0.6	-0.59	-0.17	-0.34	-0.13	-0.56	0.42	-0.08	-0.18	-0.49		-0.48	0.14	0.27	0.37	0.0	0.06	-0.57	-0.34	-0.54
Common Stock Total Equity	0.73	0.54	0.26	0.83	-0.81	-0.86	0.82	0.83	-0.2	0.89	0.26	0.73	-0.77	-0.2	0.31	0.85	-0.48		-0.6	-0.78	-0.56	0.29	0.48	0.67	0.58	0.84
Short Long Term Debt Total	-0.11	-0.23	-0.12	-0.35	0.32	0.59	-0.36	-0.36	0.1	-0.64	-0.12	-0.1	0.51	0.12	0.0	-0.16	0.14	-0.6		0.37	0.3	-0.14	-0.3	-0.38	-0.28	-0.3
Short Term Debt	-0.83	-0.7	-0.22	-0.88	0.86	0.91	-0.86	-0.86	0.41	-0.89	-0.22	-0.83	0.3	0.32	-0.51	-0.73	0.27	-0.78	0.37		0.8	-0.36	-0.62	-0.35	-0.83	-0.88
Net Receivables	-0.66	-0.47	-0.01	-0.71	0.72	0.71	-0.72	-0.71	0.37	-0.68	-0.01	-0.66	0.18	0.11	-0.54	-0.5	0.37	-0.56	0.3	0.8		-0.16	-0.3	-0.05	-0.96	-0.7
Inventory	0.4	0.42	0.71	0.32	-0.33	-0.55	0.32	0.33	-0.03	0.51	0.71	0.39	0.19	-0.87	0.44	0.24	0.0	0.29	-0.14	-0.36	-0.16		0.46	0.05	0.43	0.28
Current Deferred Revenue	0.35	0.72	0.48	0.34	-0.34	-0.69	0.33	0.33	-0.31	0.65	0.48	0.34	-0.21	-0.29	0.29	0.51	0.06	0.48	-0.3	-0.62	-0.3	0.46		0.06	0.41	0.35
Net Tangible Assets	0.58	0.37	0.04	0.64	-0.63	-0.41	0.63	0.65	0.04	0.49	0.04	0.58	-0.66	0.03	-0.13	0.58	-0.57	0.67	-0.38	-0.35	-0.05	0.05	0.06		0.06	0.66
Preferred Stock Total Equity	0.72	0.55	0.2	0.73	-0.75	-0.79	0.75	0.74	-0.35	0.75	0.2	0.72	-0.11	-0.33	0.61	0.53	-0.34	0.58	-0.28	-0.83	-0.96	0.43	0.41	0.06		0.71
Net Invested Capital	0.95	0.66	0.16	0.98	-0.97	-0.81	0.97	0.98	-0.25	0.83	0.16	0.95	-0.45	-0.24	0.41	0.83	-0.54	0.84	-0.3	-0.88	-0.7	0.28	0.35	0.66	0.71

Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Current Liab	237.9K	10.5K	302.9K	394.8K	313.9K	171.6K
Total Current Liabilities	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Stockholder Equity	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M
Net Debt	(2.6M)	(5.1M)	(4.8M)	(5.4M)	(4.2M)	(4.0M)
Retained Earnings	(27.1M)	(30.4M)	(37.1M)	(43.4M)	(48.5M)	(46.1M)
Cash	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Cash And Short Term Investments	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Common Stock Shares Outstanding	1.1M	1.1M	1.3M	158.2K	1.9M	1.8M
Liabilities And Stockholders Equity	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Stockholder Equity	26.0M	31.9M	38.4M	45.1M	49.0M	51.4M
Total Liab	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Current Assets	2.7M	5.2M	5.1M	5.6M	4.2M	2.2M
Accounts Payable	143.5K	190.3K	226.0K	229.8K	156.8K	169.4K
Other Current Assets	58.8K	15K	10.2K	10.4K	27.1K	54.0K
Short Term Debt	(210.9K)	(237.9K)	(302.9K)	(394.8K)	(313.9K)	(298.2K)
Current Deferred Revenue	94.3K	15.8K	77.0K	165.0K	157.1K	81.5K
Net Tangible Assets	625.8K	(1.1M)	1.5M	1.3M	1.5M	1.6M
Net Invested Capital	(1.1M)	1.5M	1.3M	1.7M	494.8K	317K
Net Working Capital	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:

How To Invest In Lixte

Details

Is Lixte Stock a good investment?

Details

What is Lixte Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Transaction History View history of all your transactions and understand their impact on performance
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes

Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.66)

Return On Assets

(0.64)

Return On Equity

(1.11)

The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lixte Common Stock Shares Outstanding vs Cash Analysis

Common Stock Shares Outstanding vs Cash

Common Stock Shares Outstanding vs Cash Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Cash

Lixte Biotechnology fundamental ratios Correlations

Lixte Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lixte Biotechnology fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lixte Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Net Invested Capital	+ 0.98	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Net Invested Capital	- 0.97	Net Debt
Total Current Assets	- 0.97	Net Debt